## Ilinca Popp

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/814526/publications.pdf

Version: 2024-02-01

13	310	7	11
papers	citations	h-index	g-index
14	14	14	545
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Optimization of hippocampus sparing during whole brain radiation therapy with simultaneous integrated boostâ€"tutorial and efficacy of complete directional hippocampal blocking. Strahlentherapie Und Onkologie, 2022, 198, 537-546.	2.0	7
2	Hippocampus-Avoidance Whole-Brain Radiation Therapy Is Efficient in the Long-Term Preservation of Hippocampal Volume. Frontiers in Oncology, 2021, 11, 714709.	2.8	11
3	Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic Malignancies. Cancers, 2021, 13, 5725.	3.7	5
4	Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) – a phase II prospective randomized multicenter trial (NOA-14, ARO 2015–3, DKTK-ROG). BMC Cancer, 2020, 20, 532.	2.6	43
5	Long-term survival results after treatment for oligometastatic brain disease. Reports of Practical Oncology and Radiotherapy, 2020, 25, 307-311.	0.6	9
6	Hippocampusâ€avoidance wholeâ€brain radiation therapy with a simultaneous integrated boost for multiple brain metastases. Cancer, 2020, 126, 2694-2703.	4.1	41
7	Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA). Radiation Oncology, 2020, 15, 35.	2.7	6
8	Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma. Radiotherapy and Oncology, 2019, 130, 121-131.	0.6	24
9	GENE-27. GENOME-WIDE DNA METHYLATION PROFILING IN GRADE II AND III GLIOMAS REVEALS A SUBSET OF GENES WITH PROGNOSTIC SIGNIFICANCE CONTROLLED BY PROMOTER METHYLATION. Neuro-Oncology, 2018, 20, vi109-vi109.	1.2	O
10	CSIG-21. THE ROLE OF miR-219a-2-3p AS A TUMOR SUPPRESSOR IN IDH1/2-WILD-TYPE GRADE II/III GLIOMAS. Neuro-Oncology, 2018, 20, vi47-vi47.	1.2	0
11	Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1463-1472.	6.4	51
12	Approaches to improve metabolic stability of a statine-based GRP receptor antagonist. Nuclear Medicine and Biology, 2017, 45, 22-29.	0.6	14
13	Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. Radiotherapy and Oncology, 2016, 120, 185-194.	0.6	99